404 related articles for article (PubMed ID: 28122327)
21. Suppression of Tregs by anti-glucocorticoid induced TNF receptor antibody enhances the antitumor immunity of interferon-α gene therapy for pancreatic cancer.
Aida K; Miyakawa R; Suzuki K; Narumi K; Udagawa T; Yamamoto Y; Chikaraishi T; Yoshida T; Aoki K
Cancer Sci; 2014 Feb; 105(2):159-67. PubMed ID: 24289533
[TBL] [Abstract][Full Text] [Related]
22. Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma.
Klages K; Mayer CT; Lahl K; Loddenkemper C; Teng MW; Ngiow SF; Smyth MJ; Hamann A; Huehn J; Sparwasser T
Cancer Res; 2010 Oct; 70(20):7788-99. PubMed ID: 20924102
[TBL] [Abstract][Full Text] [Related]
23. Targeting CCR8 Induces Protective Antitumor Immunity and Enhances Vaccine-Induced Responses in Colon Cancer.
Villarreal DO; L'Huillier A; Armington S; Mottershead C; Filippova EV; Coder BD; Petit RG; Princiotta MF
Cancer Res; 2018 Sep; 78(18):5340-5348. PubMed ID: 30026324
[TBL] [Abstract][Full Text] [Related]
24. CD4(+) CD25(low) GITR(+) cells: a novel human CD4(+) T-cell population with regulatory activity.
Bianchini R; Bistoni O; Alunno A; Petrillo MG; Ronchetti S; Sportoletti P; Bocci EB; Nocentini G; Gerli R; Riccardi C
Eur J Immunol; 2011 Aug; 41(8):2269-78. PubMed ID: 21557210
[TBL] [Abstract][Full Text] [Related]
25. Intratumoral depletion of regulatory T cells using CD25-targeted photodynamic therapy in a mouse melanoma model induces antitumoral immune responses.
Oh DS; Kim H; Oh JE; Jung HE; Lee YS; Park JH; Lee HK
Oncotarget; 2017 Jul; 8(29):47440-47453. PubMed ID: 28537894
[TBL] [Abstract][Full Text] [Related]
26. Ptpn22 Modifies Regulatory T Cell Homeostasis via GITR Upregulation.
Nowakowska DJ; Kissler S
J Immunol; 2016 Mar; 196(5):2145-52. PubMed ID: 26810223
[TBL] [Abstract][Full Text] [Related]
27. In vivo expansion of CD4+Foxp3+ regulatory T cells mediated by GITR molecules.
Nishioka T; Nishida E; Iida R; Morita A; Shimizu J
Immunol Lett; 2008 Dec; 121(2):97-104. PubMed ID: 18930767
[TBL] [Abstract][Full Text] [Related]
28. Combination GITR targeting/PD-1 blockade with vaccination drives robust antigen-specific antitumor immunity.
Villarreal DO; Chin D; Smith MA; Luistro LL; Snyder LA
Oncotarget; 2017 Jun; 8(24):39117-39130. PubMed ID: 28388572
[TBL] [Abstract][Full Text] [Related]
29. Pivotal roles of CD4+ effector T cells in mediating agonistic anti-GITR mAb-induced-immune activation and tumor immunity in CT26 tumors.
Zhou P; L'italien L; Hodges D; Schebye XM
J Immunol; 2007 Dec; 179(11):7365-75. PubMed ID: 18025180
[TBL] [Abstract][Full Text] [Related]
30. OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy.
Bulliard Y; Jolicoeur R; Zhang J; Dranoff G; Wilson NS; Brogdon JL
Immunol Cell Biol; 2014 Jul; 92(6):475-80. PubMed ID: 24732076
[TBL] [Abstract][Full Text] [Related]
31. Synergistic antitumor responses by combined GITR activation and sunitinib in metastatic renal cell carcinoma.
Yu N; Fu S; Xu Z; Liu Y; Hao J; Zhang A; Wang B
Int J Cancer; 2016 Jan; 138(2):451-62. PubMed ID: 26239999
[TBL] [Abstract][Full Text] [Related]
32. GITR Antibodies in Cancer: Not Ready for Prime Time.
Hernandez-Guerrero T; Moreno V
Clin Cancer Res; 2022 Sep; 28(18):3905-3907. PubMed ID: 35834593
[TBL] [Abstract][Full Text] [Related]
33. A Novel Murine GITR Ligand Fusion Protein Induces Antitumor Activity as a Monotherapy That Is Further Enhanced in Combination with an OX40 Agonist.
Leyland R; Watkins A; Mulgrew KA; Holoweckyj N; Bamber L; Tigue NJ; Offer E; Andrews J; Yan L; Mullins S; Oberst MD; Coates Ulrichsen J; Leinster DA; McGlinchey K; Young L; Morrow M; Hammond SA; Mallinder P; Herath A; Leow CC; Wilkinson RW; Stewart R
Clin Cancer Res; 2017 Jul; 23(13):3416-3427. PubMed ID: 28069723
[No Abstract] [Full Text] [Related]
34. Glucocorticoid-induced TNFR-related gene (GITR) as a therapeutic target for immunotherapy.
Riccardi C; Ronchetti S; Nocentini G
Expert Opin Ther Targets; 2018 Sep; 22(9):783-797. PubMed ID: 30107134
[TBL] [Abstract][Full Text] [Related]
35. Localized expression of GITR-L in the tumor microenvironment promotes CD8+ T cell dependent anti-tumor immunity.
Cho JS; Hsu JV; Morrison SL
Cancer Immunol Immunother; 2009 Jul; 58(7):1057-69. PubMed ID: 19018533
[TBL] [Abstract][Full Text] [Related]
36. A Neuropilin-1 Antagonist Exerts Antitumor Immunity by Inhibiting the Suppressive Function of Intratumoral Regulatory T Cells.
Jung K; Kim JA; Kim YJ; Lee HW; Kim CH; Haam S; Kim YS
Cancer Immunol Res; 2020 Jan; 8(1):46-56. PubMed ID: 31554638
[TBL] [Abstract][Full Text] [Related]
37. Glucocorticoid-induced tumour necrosis factor receptor family-related receptor signalling exacerbates hapten-induced colitis by CD4+ T cells.
Lee SK; Choi BK; Kim YH; Kang WJ; Kim KH; Sakaguchi S; Suh JH; Kim TY; Kwon BS
Immunology; 2006 Dec; 119(4):479-87. PubMed ID: 17177830
[TBL] [Abstract][Full Text] [Related]
38. Modulation of tumor immunity: a patent evaluation of WO2015026684A1.
Nocentini G; Cari L; Ronchetti S; Riccardi C
Expert Opin Ther Pat; 2016; 26(3):417-25. PubMed ID: 26560753
[TBL] [Abstract][Full Text] [Related]
39. A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity.
Kumar P; Bhattacharya P; Prabhakar BS
J Autoimmun; 2018 Dec; 95():77-99. PubMed ID: 30174217
[TBL] [Abstract][Full Text] [Related]
40. Anti-GITR therapy promotes immunity against malignant glioma in a murine model.
Miska J; Rashidi A; Chang AL; Muroski ME; Han Y; Zhang L; Lesniak MS
Cancer Immunol Immunother; 2016 Dec; 65(12):1555-1567. PubMed ID: 27734112
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]